NDASUBLINGUALPOWDER
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
GONITRO (nitroglycerin) by Pfizer is (no) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic gmp) in smooth muscle and other tissues. Approved for angina pectoris, coronary artery disease. First approved in 2016.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GONITRO is a sublingual powder formulation of nitroglycerin, a vasodilator that activates guanylate cyclase to increase cyclic GMP in smooth muscle, causing vasodilatation. It is indicated for acute relief of angina pectoris and management of coronary artery disease. The drug works by relaxing vascular smooth muscle, reducing cardiac preload and afterload while dilating coronary arteries.
Peak5.9 years to LOE
GONITRO is in peak commercial phase with strong Pfizer backing; brand and field teams are likely mature and focused on market maintenance rather than expansion.
Mechanism of Action
(NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.
Indications (2)
Worked on GONITRO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.